Neuropilin-1: A Conserved Entry Receptor for SARS-CoV-2 and a Potential Therapeutic Target

Vivany Maydel Sierra-Sánchez1, Citlali Margarita Blancas-Napoles1, Aina Daniela Sánchez-Maldonado1

  • 1Laboratorio de Terapia Génica Experimental, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.

Biomedicines
|July 29, 2025
PubMed
Summary

Neuropilin-1 (NRP1) is a crucial SARS-CoV-2 co-receptor. Targeting NRP1 with siRNA effectively reduced lung injury in a preclinical model, suggesting its potential as a therapeutic target against COVID-19 variants.